DK3449939T3 - Farmaceutisk sammensætning til at hæmme metastase af kræft, omfattende, som aktiv ingrediens, antistof som specifikt binder til epidermal vækstfaktorreceptor - Google Patents

Farmaceutisk sammensætning til at hæmme metastase af kræft, omfattende, som aktiv ingrediens, antistof som specifikt binder til epidermal vækstfaktorreceptor Download PDF

Info

Publication number
DK3449939T3
DK3449939T3 DK16900546.9T DK16900546T DK3449939T3 DK 3449939 T3 DK3449939 T3 DK 3449939T3 DK 16900546 T DK16900546 T DK 16900546T DK 3449939 T3 DK3449939 T3 DK 3449939T3
Authority
DK
Denmark
Prior art keywords
metastase
pharmaceutical composition
active ingredient
growth factor
factor receptor
Prior art date
Application number
DK16900546.9T
Other languages
English (en)
Inventor
Jong-Hwa Won
Yangmi Lim
Min-Kyu Hur
Original Assignee
Green Cross Corp
Mogam Inst Biomedical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp, Mogam Inst Biomedical Res filed Critical Green Cross Corp
Application granted granted Critical
Publication of DK3449939T3 publication Critical patent/DK3449939T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK16900546.9T 2016-04-27 2016-04-27 Farmaceutisk sammensætning til at hæmme metastase af kræft, omfattende, som aktiv ingrediens, antistof som specifikt binder til epidermal vækstfaktorreceptor DK3449939T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2016/004418 WO2017188472A1 (ko) 2016-04-27 2016-04-27 표피 성장 인자 수용체에 특이적으로 결합하는 항체를 유효성분으로 포함하는 암의 전이 억제용 약학 조성물

Publications (1)

Publication Number Publication Date
DK3449939T3 true DK3449939T3 (da) 2022-05-02

Family

ID=60159801

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16900546.9T DK3449939T3 (da) 2016-04-27 2016-04-27 Farmaceutisk sammensætning til at hæmme metastase af kræft, omfattende, som aktiv ingrediens, antistof som specifikt binder til epidermal vækstfaktorreceptor

Country Status (13)

Country Link
US (1) US11198733B2 (da)
EP (1) EP3449939B1 (da)
JP (1) JP6701382B2 (da)
KR (1) KR102128556B1 (da)
CN (1) CN109195627B (da)
DK (1) DK3449939T3 (da)
ES (1) ES2912903T3 (da)
HR (1) HRP20220576T1 (da)
HU (1) HUE058745T2 (da)
LT (1) LT3449939T (da)
PL (1) PL3449939T3 (da)
SI (1) SI3449939T1 (da)
WO (1) WO2017188472A1 (da)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790164B2 (en) * 2006-11-14 2010-09-07 Van Andel Research Institute Fragments of antibodies to epidermal growth factor receptor and methods of their use
KR101108642B1 (ko) * 2009-09-29 2012-02-09 주식회사 녹십자 표피 성장 인자 수용체에 특이적으로 결합하는 항체
JP2013533211A (ja) * 2010-05-04 2013-08-22 メリマック ファーマシューティカルズ インコーポレーティッド 上皮成長因子受容体（ｅｇｆｒ）に対する抗体およびその使用
KR20130083090A (ko) 2012-01-10 2013-07-22 강원대학교산학협력단 암 세포의 ｅｇｆｒ에 특이적으로 결합하는 항체 및 이의 용도
CN104379602B (zh) 2012-03-08 2017-05-03 哈洛齐梅公司 具有条件活性的抗表皮生长因子受体抗体及其使用方法
CN104918956A (zh) 2012-05-17 2015-09-16 索伦托治疗有限公司 与egfr结合的抗原结合蛋白
US20150147309A1 (en) 2012-06-06 2015-05-28 Fondazione Telethon Allosteric chaperones and uses thereof
KR20150144804A (ko) * 2013-04-22 2015-12-28 글리코토페 게엠베하 낮은 푸코실화를 갖는 항­ｅｇｆｒ 항체를 이용한 항암 치료

Also Published As

Publication number Publication date
KR20180137502A (ko) 2018-12-27
EP3449939A1 (en) 2019-03-06
HRP20220576T1 (hr) 2022-06-10
CN109195627B (zh) 2022-09-09
JP2019514909A (ja) 2019-06-06
ES2912903T3 (es) 2022-05-30
WO2017188472A1 (ko) 2017-11-02
CN109195627A (zh) 2019-01-11
US11198733B2 (en) 2021-12-14
US20190119388A1 (en) 2019-04-25
JP6701382B2 (ja) 2020-05-27
EP3449939B1 (en) 2022-03-30
SI3449939T1 (sl) 2022-06-30
HUE058745T2 (hu) 2022-09-28
LT3449939T (lt) 2022-05-25
EP3449939A4 (en) 2019-12-18
KR102128556B1 (ko) 2020-06-30
PL3449939T3 (pl) 2022-06-20

Similar Documents

Publication Publication Date Title
DK3616720T3 (da) Farmaceutisk sammensætning til cancerbehandling
EP3470430A4 (en) INTERLEUKIN 4 RECEPTOR BINDING ANTIBODIES
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
DK2818482T3 (da) Farmaceutisk sammensætning til behandling af cancer
BR112015004489A2 (pt) composto, composição farmacêutica, e, métodos para tratar um distúrbio proliferativo e para sintetizar um composto
BR112016020112A2 (pt) anticorpos multiespecíficos, método para a preparação de um anticorpo multiespecífico, ácido nucleico, vetor de expressão e composição farmacêutica
CL2015000094A1 (es) Compuestos derivados de imidazotriazincarbonitrilos, inhibidores de la proteina cinasa; composicion farmaceutica que los comprende; y su uso para tratar el cancer, psoriasis y artritis reumatoide.
BR112015004397A2 (pt) formulações de anticorpos de receptor anti-prolactina.
CL2011002943A1 (es) Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica.
BR112014032510A2 (pt) composto, composição farmacêutica, método para tratar ou prevenir uma doença ou desordem, e, uso de um composto.
DK3634468T3 (da) Fast sammensætning til oral indgivelse
DK2741763T3 (da) Sammensætning til kontrolleret ovariestimulering.
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
BR112013031712A2 (pt) composto, composição farmacêutica, métodos para preparar um composto e para o tratamento de um distúrbio ou uma doença.
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
MA53106A (fr) Polymères liant les protons pour administration orale
BR112014008241A2 (pt) composto, composição farmacêutica, métodos para tratar, controlar, retardar ou prevenir doenças e distúrbios, e para preparar um composto, e, uso de um composto
DK3390450T3 (da) Anti-cd28-humaniserede antistoffer formuleret til indgivelse til mennesker
EP3391904A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING HUMAN TSLP ANTI-RECEPTOR ANTIBODY
BR112014016736A2 (pt) composto, composição farmacêutica, método para tratamento, uso de um composto e invenção
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina
HK1231390A1 (zh) 用於局部給藥的藥用組合物
BR112016027133A8 (pt) derivados de imidazol como moduladores do receptor de formil peptídeo, composição farmacêutica e uso
DK3672631T3 (da) Farmaceutiske sammensætninger indeholdende anti-beta-amyloid-antistoffer
BR112018002283A2 (pt) Composição para administração tópica a um sujeito, e, formulação tópica